A Four Period, Four-Arm, Crossover Design, Randomized, Placebo and Active Controlled Study for the Evaluation of the Effect of Therapeutic and Supratherapeutic Single-Dose ANX-188 on the QT/QTc Intervals in Healthy Volunteers

Trial Profile

A Four Period, Four-Arm, Crossover Design, Randomized, Placebo and Active Controlled Study for the Evaluation of the Effect of Therapeutic and Supratherapeutic Single-Dose ANX-188 on the QT/QTc Intervals in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 22 May 2015

At a glance

  • Drugs Poloxamer 188 (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Peripheral arterial occlusive disorders; Thrombosis; Venous thromboembolism
  • Focus Therapeutic Use
  • Sponsors Mast Therapeutics
  • Most Recent Events

    • 23 Jul 2013 Results published in a Mast Therapeutics Media Release.
    • 23 Jul 2013 Primary endpoint 'no effect on QT-interval' has been met, according to a Mast Therapeutics media release.
    • 23 Jul 2013 Status changed from active, no longer recruiting to completed, according to a Mast Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top